<?xml version='1.0' encoding='utf-8'?>
<document id="29412463"><sentence text="The Drug-Drug Interaction Profile of Presatovir." /><sentence text="Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in young children" /><sentence text=" Presatovir (previously GS-5806) is a novel, orally administered RSV fusion inhibitor with a favorable safety profile and proven antiviral efficacy in preclinical and clinical studies"><entity charOffset="24-31" id="DDI-PubMed.29412463.s3.e0" text="GS-5806" /></sentence><sentence text=" In vitro, presatovir is a substrate of the efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) and hepatic uptake transporters organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 and is slowly metabolized by cytochrome P450 (CYP) 3A4 and CYP3A5" /><sentence text=" This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P-gp, BCRP, and OATP1B1/1B3 inhibitor; rifampin, a strong CYP3A4 and P-gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics"><entity charOffset="67-79" id="DDI-PubMed.29412463.s5.e0" text="cyclosporine" /><entity charOffset="122-130" id="DDI-PubMed.29412463.s5.e1" text="rifampin" /><entity charOffset="166-175" id="DDI-PubMed.29412463.s5.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.29412463.s5.e0" e2="DDI-PubMed.29412463.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29412463.s5.e0" e2="DDI-PubMed.29412463.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29412463.s5.e0" e2="DDI-PubMed.29412463.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29412463.s5.e1" e2="DDI-PubMed.29412463.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29412463.s5.e1" e2="DDI-PubMed.29412463.s5.e2" /></sentence><sentence text=" Presatovir plasma exposures (maximum observed plasma concentration [Cmax ] and area under the plasma concentration-time curve from time 0 extrapolated to infinity [AUCinf ]) were not affected by coadministration of cyclosporine, suggesting presatovir is not a sensitive substrate of P-gp, BCRP, or OATP1B1/1B3"><entity charOffset="216-228" id="DDI-PubMed.29412463.s6.e0" text="cyclosporine" /></sentence><sentence text=" As expected, based on the role of CYP3A in presatovir metabolism, presatovir exposure was increased by cobicistat (122% in AUCinf ), and decreased by rifampin (40"><entity charOffset="151-159" id="DDI-PubMed.29412463.s7.e0" text="rifampin" /></sentence><sentence text="3% in Cmax and 82" /><sentence text="5% in AUCinf ) and efavirenz (55"><entity charOffset="19-28" id="DDI-PubMed.29412463.s9.e0" text="efavirenz" /></sentence><sentence text="7% in AUCinf )" /><sentence text=" These data support coadministration of presatovir with inhibitors of P-gp, BCRP, OATP1B1/1B3, or CYP3A, but not with moderate or strong CYP3A4 inducers" /><sentence text=" Presatovir was well-tolerated with the most common drug-related adverse events of dizziness (n = 12) and somnolence (n = 4) reported during efavirenz treatment"><entity charOffset="141-150" id="DDI-PubMed.29412463.s12.e0" text="efavirenz" /></sentence><sentence text="" /></document>